PAPER
Large-Scale Synthesis of Benzazepinone Derivatives
2469
petroleum ether (bp 40–60 °C) (200 mL) was added. The brown so-
lution was cooled to 5–10 °C for 2 h to obtain a slurry, which upon
filtration and drying provided a brownish solid; yield: 36 g (78%);
purity: 96.5%; mp 107–114 °C.
1H NMR (DMSO6): δ = 1.77 (m, 2 H), 2.0 (s, 3 H), 2.13 (s, 3 H),
2.33 (m, 2 H), 3.02 (m, 2 H), 6.42 (d, J = 4.4 Hz, 1 H), 6.7 (m, 2 H),
11.97 (br, 1 H).
Acknowledgment
We are thankful to PharmExplorer and WuXi Pharmatech scientists
for providing the data. Professors M. Miller and W. Roush, Dr. Rick
Berglund, and Dr. T. Zhang are acknowledged for thoughtful
discussions and valuable suggestions. Prof. Z. Zhang is acknow-
ledged for providing compound 13 required in the synthesis of com-
pound 6. We are also thankful to Lisa Zollars for providing NMR
data of various compounds.
13C NMR (CDCl3): δ = 175.1, 144.9, 131.0, 127.4, 124.2, 122.3,
108.6, 43.1, 31.9, 24.5, 20.6, 18.1;
HRMS: m/z [M]+ calcd C12H17NO2: 207.1259; found: 207.1256.
Supporting Information for this article is available online
at
Conversion of 6 into 10
10.1055/s-00000084.SunogIpimrfiantoSuIpg
n
fonirtat
ori
To a dried 1 L round-bottomed flask was added 6 (35.0 g, 168.9
mmol), THF (300 mL), K2CO3 (50.0 g, 361.8 mmol), and methyl
chloroformate (20 mL, 1.59 equiv). The brown heterogeneous mix-
ture was stirred at 25–30 °C for 14 h. LCMS data indicated the for-
mation of the desired product 10. The reaction mixture was filtered
and the cake was washed with CH2Cl2 (200 mL). The product was
extracted into aqueous phase by treating the CH2Cl2 layer with 2 M
NaOH (200 mL). The aqueous layer was extracted by CH2Cl2 (50
mL) and the combined organic phases were discarded. The pH of
the aqueous layer was adjusted to 1–2 by aq 6 M HCl. The product
was extracted with CH2Cl2 (2 × 100 mL). The brownish organic lay-
er was separated, dried (MgSO4), and concentrated to give a brown
viscous oil; yield: 40 g (88%); purity: 95.7%.
References
(1) (a) So, M.; Kotake, T.; Matsurra, K.; Kamimura, A. J. Org.
Chem. 2012, 77, 4017. (b) Hoyt, S. B.; London, C.; Park, M.
Tetrahedron Lett. 2009, 50, 1911. (c) Qadir, M.; Cobb, J.;
Sheldrake, P. W.; Whittall, N.; White, J. P.; Hii, K. K.;
Horton, P. N.; Hursthouse, M. B. J. Org. Chem. 2005, 70,
1545.
(2) (a) Moni, L.; Banfi, L.; Basso, A.; Galatini, A.; Spallarossa,
M.; Riva, R. J. Org. Chem. 2014, 79, 339. (b) Gilchrist, T. L.
Heterocyclic Chemistry, 3rd ed.; Addison Wesley: Essex,
1997, 414.
Compounds 17–19
Compounds 17–19 were synthesized following procedure described
for compound 1 starting from the corresponding aniline (85 mmol).
(3) (a) Kametani, T.; Fukumoto, K. Heterocycles 1975, 3, 931.
(b) Kouznetsov, V.; Palma, A.; Ewert, C. Curr. Org. Chem.
2001, 5, 519. (c) Meigh, J-P. K. In Science of Synthesis; Vol.
17; Weinreb, S. M.; Schaumann, E., Eds.; Thieme: Stuttgart,
2004, 825–927.
Compound 17
Yield: 5 g (62%); viscous oil.
1H NMR (DMSO-d6): δ = 7.49–7.48 (m, 1 H), 7.38–7.29 (m, 1 H),
7.30–7.28 (m, 1 H), 3.70 (t, J = 6.5 Hz, 2 H), 3.64 (s, 3 H), 2.61–
2.48 (m, 2 H), 2.33 (s, 3 H), 1.98–1.94 (m, 2 H).
13C NMR (CDCl3): δ = 200.6, 154.7, 139.1, 135.8, 133.4, 133.0,
128.0, 127.9, 52.4, 52.4, 47.5, 22.6, 19.9.
HRMS: m/z [M + Na]+ calcd for C13H15NO3 + Na: 256.0941; found:
256.0944.
(4) (a) Albright, J. D.; Reich, M. F.; Delos Santos, E. G.; Dusza,
J. P.; Sum, F. W.; Venkatesan, A. M.; Coupet, J.; Chan, P.
S.; Ru, X.; Mazandarani, H.; Bailey, T. J. Med. Chem. 1998,
41, 2442. (b) Kondo, K.; Ogawa, H.; Shinohara, T.;
Kurimura, M.; Tanada, Y.; Kan, K.; Yamashita, H.;
Nakamura, S.; Hirano, T.; Yamamura, Y.; Mori, T.;
Tominaga, M.; Itai, A. J. Med. Chem. 2000, 43, 4388.
(c) Wyatt, P. G.; Allen, M. J.; Chilcott, J.; Hickin, G.; Miller,
N. D.; Woollard, P. M. Bioorg. Med. Chem. Lett. 2001, 11,
1301. (d) Kondo, K.; Kan, K.; Tanada, Y.; Bando, M.;
Shinohara, T.; Kurimura, M.; Ogawa, H.; Nakamura, S.;
Hirano, T.; Yamamura, Y.; Kido, M.; Mori, T.; Tominaga,
M. J. Med. Chem. 2002, 45, 3805. (e) Pitt, G. R. W.; Batt, A.
R.; Haigh, R. M.; Penson, A. M.; Robson, P. A.; Rooker, D.
P.; Tartar, A. L.; Trim, J. E.; Yea, C. M.; Roe, M. B. Bioorg.
Med. Chem. Lett. 2004, 14, 4585. (f) Failli, A. A.; Shumsky,
J. S.; Steffan, R. J.; Caggiano, T. J.; Williams, D. K.;
Trybulski, E. J.; Ning, X.; Lock, Y.; Tanikella, T.;
Hartmann, D.; Chan, P. S.; Park, C. H. Bioorg. Med. Chem.
Lett. 2006, 16, 954.
Compound 18
Yield: 4 g (60%); mp 79–81 °C; purity: 96.2%.
1H NMR (DMSO-d6): δ = 7.51 (d, J = 7.5 Hz, 1 H), 7.47–7.38 (m,
1 H), 7.38–7.28 (m, 1 H), 4.24 (ddd, J = 6.6, 10.1, 13.2 Hz, 1 H),
3.51 (s, 2 H), 3.19 (ddd, J = 2.9, 6.8, 13.2 Hz, 1 H), 2.68–2.55 (m,
1 H), 2.46–2.29 (m, 1 H), 2.21–2.12 (m, 3 H), 2.03 (br s, 1 H), 2.11–
1.95 (m, 1 H), 1.74–1.45 (m, 1 H).
13C NMR (CDCl3): δ = 203.8, 155.8, 137.8, 136.8, 136.7, 135.2,
128.5, 126.6, 53.4, 53.4, 45.6, 21.7, 17.1.
HRMS: m/z [M + Na]+ calcd for C13H15NO3 + Na: 256.0941; found:
256.0946.
(5) Nicholls, S. J.; Brewer, H. B.; John, J. P.; Kastelein, J. J. P.;
Krueger, K. A.; Wang, M-D.; Shao, M.; Hu, B.; McErlean,
E.; Nissen, S. E. JAMA 2011, 306, 2099; and references cited
therein.
(6) Chen, X.; Frank, S. A.; Remick, D. M.; Pedersen, S. W. US
Patent 331309 A1, 2010; Chem. Abstr. 2011, 154, 118675.
(7) Ma, F.; Xie, X.; Ding, L.; Gao, J.; Zhang, Z. Tetrahedron
2011, 67, 9405; and references cited therein.
(8) Xie, X.; Zhang, T. Y.; Zhang, Z. J. Org. Chem. 2006, 71,
6522.
(9) Gajda, T.; Zwierzak, A. Synthesis 1981, 1005.
(10) Brehme, R. Synthesis 1976, 113.
Compound 19
Yield: 7 g (65%); mp 123–125 °C.
1H NMR (DMSO-d6): δ = 7.05 (s, 1 H), 6.91 (s, 1 H), 3.65 (br s, 2
H), 3.56 (s, 3 H), 2.55–2.43 (m, 3 H), 2.29 (s, 3 H), 2.23 (s, 3 H),
1.87–1.71 (m, 2 H).
13C NMR (CDCl3): δ = 205.9, 155.4, 140.6, 138.1, 136.3, 133.8,
130.7, 126.3, 52.6, 46.9, 40.7, 22.5, 20.6, 19.0.
HRMS: m/z [M + H]+ calcd for C14H17NO3: 248.1208; found:
248.1206.
(11) Koziara, A.; Zawadzki, S.; Zwierzak, A. Synthesis 1979,
527.
© Georg Thieme Verlag Stuttgart · New York
Synthesis 2014, 46, 2463–2470